Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $115 million by offering 7.2 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Blueprint Medicines would command a fully diluted market value of $421 million.
Blueprint Medicines, which was founded in 2008, plans to list on the NASDAQ under the symbol BPMC. Goldman Sachs and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of April 27, 2015.
